INNOVATE Corp (VATE)

Despite the upward progress, there seems to be no interest in VATE. I'm at a loss to understand that at this point.

As I predicted, there will be some entry points for VATE on it's way to a $30 stock.
Toady, at under $10, is one of those days.
Remember, this stock did a 1-10 reverse split, so today's price is equivalent to less than $1/ share, per-split.

Shares bought here will make a LOT of money-- at least 300%, IMO.

VATE has made a big move since the January 17th FDA approval of the MediBeacon kidney function monitoring device (that has a market value north of $400 million- see https://www.biogeneratorventures.com/news-media/biogenerator-company-medibeacon-transdermal-gfr-system-receives-fda-approval-to-assess-kidney-function). The MediBeacon product alone justifies a share price of over $30.

But I would be a little cautious chasing the shares beyond $15 or so, given the fact that there will be no revenue from this new product in Q4, and the company has shown erratic earnings this past year. It bounced from a signiifcant loss in Q1, to $1.00/share earning in Q2 (on a post reverse split basis), to another loss in Q3. So who knows what we will see when they report in early March.

Long term, it is a $30-$50 stock, but there will likely be some entry points along the way, at less than $12-15.

What strange 'VATE' is at work her??!! (Remember that line in the old "TEN COMMANDMENTS" movie?? When MOSES finally meets his REAL Mother --- whom he had saved from that big Egyptian construction STONE??)

VATE: And this damn 'PHOENIX' has risen AGAIN, for God's sake!!!

VATE: "COMING-OUT-OF-BEASTVILLE" (Might be a great TITLE for your looming BOOK on Charts, Wall Street, & otherwise TRADING stocks!!)

VATE (& @WLGS): Indeed, about VATE!!! (Early today, I almost posted --- what you see below here --- to VATE's Board, because I too was astonished as to the impossible spectrum of STUFF & THINGS that VATE does!!)

"Industry, Construction & Engineering:
Innovate Corp. is a diversified holding company. The Company has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure (DBMG), Life Sciences (Pansend), and Spectrum. DBM Global Inc. (DBMG) is a fully integrated construction company offering both construction and professional services primarily through its core subsidiaries. It provides services, including design-assist, modularization, fabrication and erection of structural steel, heavy steel plate, trusses and girders, heavy equipment installation, as well as facility services for maintenance and shutdowns. DBMG manufactures pressure vessels, strainers, filters, and separators. Life Sciences segment is comprised of Pansend Life Sciences, LLC, which is focused on supporting healthcare and biotechnology product development. Spectrum segment is comprised of HC2 Broadcasting Holdings Inc. and its subsidiaries. It owns and operates broadcast television stations throughout the United States. Headquarters, 295 MADISON AVENUE, 12TH FLOOR, New York, NY"

PROBABLY AN ACCIDENT...THEY WERE DRIVING THAT TRAIN FAST.....LOOKS LIKE A SMALL HERD OF SHEEP GOT RUN OVER.

VATE: And iHub's BEST-WIT-OF-THE-DAY award goes to 'TT-2016' for:

"SOME CONSTRUCTION AT EXIT 10.94....COMING OUTTA BEASTVILLE"

I HAD NO IDEA THEY HAD A BIO SIDE TO THEIR BIZ...WLGS BEASTING

VATE: It was a NICE one, Dude!! (And as you surely know, iHub Peeps best be checking-in periodically every day to see what YOU, Homeboy, are posting about!!! Such GOOD be quite lucrative, for anybody!! Even for a Class CLOWN like me!!)

BEASTING IN BEASTVILLE...WEEKLY NOT IN BEASTVILLE...FOUND THIS BEAST WAY BACK IN BEASTVILLE...BUT I MISSED THIS ROAD TO THIS BEASTVILLE...SOME CONSTRUCTION AT EXIT 10.94....COMING OUTTA BEASTVILLE

VATE: Attention all iHub Passengers, this is your VATE stock flight Copilot, "Invest-In-America", speaking --- Jupiter's Moon, GANYMEDE, is now in sight; so you may now order your free LATTES, at your leisure; and THANKS for participating!!

That VATE 8.75 resistance break was the ticket for the win!

VATE: See latest 'CHART' on this cute little PUSSY-Cat, below!!

"Hey, Pres. Trumpster, ya wanna join me in my VATE stock Short-SQUEEZE play, Homeboy!!?? Heck, that old PornHub hooker, Stormy Daniels, ain't got nothing on ME, Trumpster Dude!! And lastly, there's OTHER stuff a Presidential STUD like you can go DRILLING for --- besides silly Gas, Oil, & Coal, Dude!! No PUNS intended, Commander-&-Trumpy, Sir!!"
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

VATE: SLAP-THAT-FLUCKIN'-ASK --- and call it DAPHNE!!!!

Flip some at high $8s and go from there 

VATE: Halted --- hopefully, on the way to JUPITER!!!

VATE: Hey, Homeboy, kick-me-down a few GRAND, will ya, behind you nice score over on your @ASST gambit already this lovely Wall Street morning --- pretty PLEASE, Boss????? (Heck, nice ASST'ed LIVING routine on THAT one!!!)

Back to $8s later $7.04 + 35%

VATE: Celebratory Lattes are on me --- a little later today --- at the new Star Bucks on Jupiter's cute moon, Ganymede!!

VATE: Oh, & one last thing. Only TWO "Monuments" should be left standing in Wash., DC --- MLK's, & Lincoln's!!! And that cute POND, & those Cherry Trees too. Other than that, REMOVE the rest!! (And I'm a 'White Guy' posting this.)

VATE: Very-well-stated, Sir!!! (And I myself normally TRASH so-called "Medical Science" on this primitive Planet.)

$VATE Rarely do you get a product that is this good for humanity, and you get to buy it and trade it on the stock market.
This Transdermal GFR will be a huge step forward for nephrology and CKD (Chronic Kidney Disease) patients.
This is extra DD for those who want more information. This is a 400 million dollar product before the clinical trials.
It's probably worth billions now that it is FDA-approved.
I'm sure this will be used in every state in the U.S. & most countries worldwide. They have done clinical trials in the U.S. & U.K. It's ok to be excited.


Transdermal GFR DD

VATE: THANKS for heads-up!!!

$VATE Grabbed a boatload. HUGE NEWS!!!
Ready for Tuesday.
Glad I checked your posts one last time before the extended hours ended.
This is huge. Thanks bro.

Monster awake again on Friday night kidney news $8s now + 60%

VATE NEXT MONSTER

Earning out.... aloss this quarter after last quarter earnings of $1/share.
They are moving forward, but it seems like always 2 steps forward, one step back.

... I guess the move up was a headfake.
Now bobbing around at about 3.3/share.
This is a stock that has a reliable income from it's construction division, and several possible surprise revenue streams from the broadcast properties as well as a couple of healthcare operations.

Any one of them could send the stock to double it's current price, very quickly. Slowly adding to my position here. It's as safe as they come, IMHO

... I guess the move up was a headfake.
Now bobbing around at about 3.3/share.
This is a stock that has a reliable income from it's construction division, and several possible surprise revenue streams from the broadcast properties as well as a couple of healthcare operations.

Any one of them could send the stock to double it's current price, very quickly. Slowly adding to my position here. It's as safe as they come, IMHO

VATE finally making it's move upward, after months of sub-par performance.
Bought some this week around $4, hoping that the rally continues.
It should- earnings last QUARTER, split-adjusted, were $1/share.

Yes, that's right, split adjusted, the earnings for the last quarter were $1. That implies a P/E ratio of 1, if they can continue to be profitable.

VATE new 52=low

So, VATE management seems to have mastered poor timing on the reverse stock split.
Why they scheduled the stock split to take effect the day after releasing earnigns makes no sense to me.
Had the stock split taken place Aug 2, as originally announced, the split adjusted earnings would have come in at $1.00 a share, for the quarter, for a stock trading at around $5/ share.
As it was done, the earnings show as .10/share on August 8, but that is before the 1:10 reverse split, that took effect after the close on 8-8, which certainly causes confusion. Just stupid, IMO.
But the satock does look like a screaming buy at $4.50/share, with quarterly earnings at $1/share. And this is before apporval of the kidney monitoring system they have been working to get through the FDA process for several years. Once that clears, they should have a huge bump in earnings and interest.
Trading now at annualized 1x earnings-- just crazy cheap.

VATE new 52 week low

VATE: Big new revs. news.

VATE new 52=week low

Over-reaction to earnings miss today. As they said on the conference call, a lot of the miss is timing issues related to the infrastructure business. They still have a huge backlog, and are generating better margins than in the past.

So I bought some more here under $2.00.

I think I'll be pretty happy with those down the road.

I bought some on his recommendation as well. Added some today just before the nice pop we saw. Be interesting to see what the earnings are on the 14th...

GL

New board follower here.... bought some on recommendation of Chris DeMuth, (Sifting the World, on Seeking Alpha) who says this is way undervalued.
He made me a nice chunk of change last year on a misunderstood litigation play.
He likes that it is a conglomerate when conglomerates are out of favor, and that it has regular income production from DBM Global (also an infrastructure play), plus some wild card businesses in health science that could be big winners.

He says it could be worth $15-20/ share, that could be unlocked in 2023.

He recommended at around this price on Jan 4.... it's been about below that price until today.

VATE is enjoying another good morning today.

WOOOOOOOOOOOOOOW 82000 SHARE BUY@1.50 PLUS 3- 11000 SHARE BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

VATE deserves some attention, recovering very well lately.

Same activist MG Capital in Contura

I own stock and boatload warrants

I bought bunch, oversubscribed

HC2 Holdings Announces Closing of Rights Offering (11/25/20)

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, announced today the closing of its successful rights offering, which expired at 5:00 p.m., New York City time, on November 20, 2020. Pursuant to the terms of the rights offering, 13,979,674 shares of common stock are being purchased pursuant to the exercise of basic subscription rights and 2,763,148 shares of common stock are being purchased under the over-subscription privilege.

In addition, in accordance with the Investment Agreement entered into by the Company with Lancer Capital LLC (“Lancer Capital”), an investment fund led by Avram Glazer, the Chairman of the Board of Directors of the Company and the Company’s largest stockholder, Lancer Capital partially backstopped the rights offering in the amount of $21,433,793.53 by purchasing Series B Non-Voting Convertible Participating Preferred Stock, par value $0.001 per share (the “preferred stock”), excluding $5,560,000 previously purchased. Concurrently with the closing of the rights offering, Lancer Capital converted all of its shares of preferred stock into 11,891,539 shares of common stock (the “conversion”).

In the aggregate, the Company is issuing 28,634,361 new shares of common stock at the subscription price of $2.27 per whole share for total gross proceeds of approximately $65 million to the Company, which includes shares of common stock issued to Lancer Capital pursuant to the conversion. After giving effect to the rights offering and the conversion, the Company will have 76,586,573 shares of common stock issued and outstanding.

HC2 expects to use the proceeds from the rights offering for general corporate purposes, including debt service and for working capital.

Investors who have participated in the rights offering should expect to see the shares of common stock issued to them in uncertificated book-entry form. Any excess subscription payments received by Computershare Trust Company, N.A. (the "subscription agent") will be returned by the subscription agent to investors, without interest or deduction, through the same method by which they participated in the rights offering.

The rights offering was made pursuant to HC2’s effective shelf registration statement on Form S-3, filed with the SEC on September 9, 2020, and a prospectus supplement containing the detailed terms of the rights offering filed with the SEC on October 7, 2020. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction. The rights offering was made only by means of a prospectus and a related prospectus supplement, copies of which were distributed to all eligible stockholders as of October 2, 2020 on or about October 7, 2020 and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

About HC2

HC2 Holdings, Inc. is a publicly traded (NYSE:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across multiple reportable segments, including Infrastructure, Clean Energy, Life Sciences, Spectrum, Insurance and Other. HC2’s largest operating subsidiary is DBM Global Inc., a family of companies providing fully integrated structural and steel construction services. Founded in 1994, HC2 is headquartered in New York, New York.

https://www.globenewswire.com/news-release/2020/11/25/2134116/0/en/HC2-Holdings-Announces-Closing-of-Rights-Offering.html

Just In: $HCHC HC2 Holdings to Announce Third Quarter 2020 Financial Results

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it will release its financial results for the third quarter 2020 on Monday, November 9, 2020 after the market closes. The Company will host an earnings confe...

In case you are interested HCHC - HC2 Holdings to Announce Third Quarter 2020 Financial Results

Falcone is good; 1st HRG now HCHC...

* * $HCHC Video Chart 02-10-2020 * *

Link to Video - click here to watch the technical chart video

* * $HCHC Video Chart 11-13-18 * *

Link to Video - click here to watch the technical chart video